Why Childhood Cancer Is Hard to Research — and What Is Changing

September is Childhood Cancer Awareness Month. On September 14, 2026, the National Cancer Institute published a talk with Dr. Brigitte Widemann. She leads the Pediatric Oncology Branch in NCI's Center for Cancer Research. She also advises the NCI director on childhood cancer. She treats children at the NIH Clinical Center and works on rare tumors and inherited conditions that raise cancer risk.

One number from that conversation explains most of the rest of it.

Every childhood cancer is a rare cancer

Dr. Widemann's point is that all cancers in children are rare. Some are very rare. A few types are found in only 40 to 50 children a year in the whole United States.

That single fact creates most of the difficulty:

• Expertise is hard to build. A doctor may see a particular tumor once or twice in a career.
• Studies are hard to run. A trial needs enough participants to tell a real effect from chance. If there are 45 children a year in the country, a trial at one hospital is not possible.
• Commercial interest is smaller. As the NCI post notes, companies have less reason to make drugs for these cancers. Adult cancers have far more patients.

None of that makes the cancers less serious to the family living with one. It just means the usual machinery of medical research does not fit.

What gets built to work around it

So the answer has mostly been to link hospitals together. No single one will ever have enough patients on its own.

The NCI post describes the Children's Oncology Group. It is a clinical trials network with more than 200 member sites. The post also names the Pediatric Early Phase Clinical Trials Network, the Pediatric Immunotherapy Network and the myPART network for rare tumors. The Childhood Cancer Data Initiative, launched in 2019, exists to pool data across those places. Its Molecular Characterization Initiative offers detailed tumor testing at the time of diagnosis, with results returned within two to three weeks.

This is why families are so often asked about a clinical trial early in a child's cancer care. Sometimes a trial is the standard path, not a last resort. In a disease with 45 cases a year, the trial is frequently where the best available knowledge lives.

Two advances she points to

The conversation names two:

• Adding the immunotherapy drug blinatumomab to chemotherapy "substantially improved disease-free survival" for children with B-cell acute lymphoblastic leukemia. Fewer children had the cancer come back.
• Atezolizumab was approved by the FDA for alveolar soft part sarcoma, an extremely rare cancer in children that previously had no approved treatment.

She also stresses what comes after. Researchers need to study the long-term effects of newer treatments, including immunotherapy. That means effects on mental health, fertility, work and relationships in people who had cancer as children. Surviving is the beginning of the question, not the end of it.

What this does not mean

• It does not describe any individual child's outlook. A conversation about research strategy says nothing about one child's diagnosis, treatment or chances. That belongs with the treating team.
• It does not mean the named advances apply broadly. Blinatumomab was discussed for one leukemia type; atezolizumab was approved for one very rare sarcoma. Neither is general childhood cancer news.
• It does not mean a trial is right for every family. Trials have eligibility rules, travel demands and unknowns. Being asked about one is an invitation to ask questions, not an obligation.
• It does not settle the long-term picture for newer treatments. That is stated in the source as work still underway, which is the honest position.

What to ask a child's care team

• Is a clinical trial part of standard care for this diagnosis? Is there one my child can join?
• Has my child's tumor had molecular testing, and when will those results come back?
• Which center in our region sees this diagnosis most often, and would a second opinion there be useful?
• What long-term follow-up will my child need after treatment ends, and who arranges it?

How this article was prepared

An AI-assisted editorial system helped prepare this page. It used the National Cancer Institute's Cancer Currents interview of September 14, 2026. It was opened on the source-check date shown above. No named medical reviewer has reviewed it unless one is listed.

Cancer Explained is published by the National Cancer Information Foundation. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.